Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery

PURPOSE: Glial-derived neurotrophic factor (GDNF) is a potential therapy for stroke, Parkinson’s disease, or drug addiction. However, GDNF does not cross the blood-brain barrier (BBB). GDNF is re-engineered as a fusion protein with a chimeric monoclonal antibody (MAb) to the human insulin receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardridge, William M., Boado, Ruben J.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2009
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737114/
https://www.ncbi.nlm.nih.gov/pubmed/19609743
http://dx.doi.org/10.1007/s11095-009-9939-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737114/
https://www.ncbi.nlm.nih.gov/pubmed/19609743
http://dx.doi.org/10.1007/s11095-009-9939-6

Ejemplares similares